MediGene AG · LS:A40ESG
MediGene — H1 2015 Earnings Presentation
19 slides from MediGene's earnings presentation, Aug 6, 2015
Slide 1: Analyst Conference Call: Results for the first 6 months of 2015
ANALYST CONFERENCE CALL Results for the first 6 months of 2015 Dr. Frank Mathias, CEO Peter Llewellyn-Davies, CFO Prof. Dolores J. Schendel, CSO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Major events since the beginning of 2015
Major events since the beginning of 2015 Gross proceeds of €46.4 m raised from the successful capital increase to finance immunotherapy programmes Initiation of phase I/II trial with DC vaccine for the treatment of acute myeloid leukaemia (AML) Progress in phase I/II DC trial triggered milestone pay
Slide 4: Financial Report 6M 2015
medigene Financial Report 6M 2015
Slide 5: Financial overview for the first 6 months of 2015
Financial overview for the first 6 months of 2015 Increase in research and development expenses Significant investments in the area of immunotherapy programmes Increased EBITDA loss as planned Increase in royalties from Veregen® Decrease in selling and general administrative expenses 5
Slide 6: Significant investments in immunotherapies
Significant investments in immunotherapies In € m R&D expenses Investments in immunotherapy +289% 4.1 2.6 3.4 +21% 0.7 6M 2014 6M 2015 6M 2014 6M 2015 R&D expenses: Significant investments in Increase due to planned the area of immunotherapy expenses in immunotherapies programmes of €2,582 k Increas
Slide 7: Administration expenses reduced
Administration expenses reduced In € m SG&A expenses 3.9 -11% 3.5 6M 2014 6M 2015 Lower costs due to one-off Trianta acquisition expenses in 2014 7
Slide 8: Planned increase in EBITDA loss
Planned increase in EBITDA loss In € m EBITDA 6-Months net result -1.6 +161% -4.3 -2.8 +115% -6.1 6M 2014 6M 2015 6M 2014 6M 2015 Increase in EBITDA loss due to lower revenues and higher expenses Increase in net loss due to lower EBITDA and Cowen currency (non-cash) book revaluation 8
Slide 9: Increase in Veregen royalties
Increase in Veregen® royalties In € m Veregen® In-market sales Total Veregen® revenue +14% 7.0 7.9 2.6 -47% 1.4 6M 2014 6M 2015 6M 2014 6M 2015 Revenue (in € k) H1 2015 H1 2014 Change Veregen® Royalties 1,182 1,018 16% Product revenue (supply chain) 156 837 -81% Milestone payments 25 700 -96% Verege
Slide 10: Financial guidance 2015 confirmed
Financial guidance 2015 confirmed 2014 Guidance 2015 double digit percentage Veregen® royalties €2.4 m increase Veregen® total revenue €5.2 m stable R&D expenses €2.9 m €7-9 m Immunotherapies EBITDA loss €2.1 m €11-13 m 10
Slide 11: Funding for immunotherapy platforms through capital measure successfully completed
Funding for immunotherapy platforms through capital measure successfully completed Raising of €46.4 m by issuance of 5,594,178 new shares Placement of all offered new shares for a subscription price of EUR 8.30 Participation of new renowned institutional investors from USA and Europe, including QVT,
Slide 12: Capital measure added new institutional investors
Capital measure added new institutional investors* After capital measure 15,6% QVT 10,0% Aviva SynCore Before capital measure Ridgeback 10,1% 3,9% DJS Montana 5,5% 58,2% RTW Master Fund Aviva 5,0% 5,0% SynCore Freefloat ** 4,4% Ridgeback 3,3% 3,9% DJS Montana 4,0% RTW Master Fund 71,1% Freefloat **
Slide 13: Focus immunotherapies - Outlook
Focus immunotherapies - Outlook
Slide 14: Medigene's immunotherapy pipeline
Medigene‘s immunotherapy pipeline PROJECT INDICATION PRECLINICAL PHASE I PHASE II PHASE III APPROVAL MARKET DC vaccine Prostate cancer* DC vaccine AML** DC vaccine AML TCRs Cancer Leukaemia and TABs autoimmune d. * investigator initiated trial (IIT) Oslo University Hospital ** investigator initiated
Slide 15: Outlook for immunotherapy platforms
Outlook for immunotherapy platforms DCs Deliver therapeutic data in patients vaccinated for more than 1.5 years Conduct the company-sponsored phase I/II study in AML Continue investigator-initiated trials and compassionate use programme TCRs Isolate TCRs with optimal affinities for lead candidate ta
Slide 16: Anticipated and completed milestones (summary)
Anticipated and completed milestones (summary) Expand pipeline with three immunotherapy programs Q1/Q2 2014 (DC/TCR/TABs) acquisition of Trianta Integrate Trianta (now Medigene Immunotherapies) and Q2/Q3 2014 establish R&D team Raise capital and expand lab capabilities Q3/Q4 2014 Present dat
Slide 17: inspired by immunotherapies
inspired by immunotherapies
Slide 18: Questions & Answers
medigene Questions & Answers
Slide 19: Medigene AG
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg Planegg/Martinsried / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG1, (MDG, Prime PrimeStandard) Standard)